This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ørbo, A. Articles by Mutter, G. L. Search for Related Content PubMed PubMed Citation Articles by Ørbo, A. Articles by Mutter, G. L.

Regression of Latent Endometrial Precancers by Progestin Infiltrated Intrauterine Device

¹ Department of Pathology, University of Tromso, Tromso, Norway and ² Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts

Requests for reprints: George L. Mutter, Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. Phone: 617-732-6096; Fax: 617-738-6996; E-mail: gmutter{at}rics.bwh.harvard.edu.

PTEN tumor suppressor inactivation is the earliest step in endometrial carcinogenesis, occurring in morphologically unremarkable endometrial glands in half of normal women. We test the hypothesis that sex hormones positively or negatively select for these "latent precancers" by examining their emergence, persistence, and regression rates under differing hormonal conditions. Perimenopausal and postmenopausal women had an intake endometrial biopsy and underwent hormonal therapy with progestin-impregnated intrauterine device (IUD; n = 21), cyclic oral progestins (n = 28), or surveillance only (n = 22) with follow-up biopsies. For comparison, premenopausal naturally cycling endometrial biopsies were studied as single time points in 87 patients and multiple surveillance time points in 34 patients. Biopsies in which any PTEN protein-null glands were found by immunohistochemistry were scored as containing a latent endometrial precancer. All groups had a similar proportion of latent precancers at intake but differed after therapy. Emergence rates were highest (21%) for the naturally cycling premenopausal group compared with just 9% for untreated perimenopausal women. The IUD group had the highest rate of regression, with a 62% pretherapy and 5% post-therapy rate of latent precancers. This contrasted to nonsignificant changes for the oral progestin and untreated control groups. Delivery of high doses of progestins locally to the endometrium by IUD leads to ablation of preexisting PTEN-inactivated endometrial latent precancers and is a possible mechanism for reduction of long-term endometrial cancer risk known to occur in response to this hormone. (Cancer Res 2006; 66(11): 5613-7)

This article has been cited by other articles:

				J. Wilkens, A.R.W. Williams, K. Chwalisz, C. Han, I.T. Cameron, and H.O.D. Critchley Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN Hum. Reprod., May 1, 2009; 24(5): 1036 - 1044. [Abstract] [Full Text] [PDF]

				G. C. Rodriguez, B.J. Rimel, W. Watkin, J. M. Turbov, C. Barry, H. Du, G. L. Maxwell, and J.M. Cline Progestin Treatment Induces Apoptosis and Modulates Transforming Growth Factor-{beta} in the Uterine Endometrium Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 578 - 584. [Abstract] [Full Text] [PDF]

				K. Ushijima, H. Yahata, H. Yoshikawa, I. Konishi, T. Yasugi, T. Saito, T. Nakanishi, H. Sasaki, F. Saji, T. Iwasaka, et al. Multicenter Phase II Study of Fertility-Sparing Treatment With Medroxyprogesterone Acetate for Endometrial Carcinoma and Atypical Hyperplasia in Young Women J. Clin. Oncol., July 1, 2007; 25(19): 2798 - 2803. [Abstract] [Full Text] [PDF]